Author:
Miyata Toshio,Ando Tsuyoshi,Hiragi Hisami,Watanabe Kanako,Yamamoto Fumi,Vaughan Douglas E.,Kurokawa Tatsuo,Oshima Yoshiteru,van Ypersele de Strihou Charles,Takeuchi Masahiro
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. US Department of Health and Human Services. Innovation or stagnation—challenge and opportunity on the critical path to new medical products. US Food and Drug Administration
[online]
, (2004).
2. Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683 (2004).
3. US Department of Health and Human Services. CDER approval times for priority and standard NDAs and BLAs calendar years 1993–2008. US Food and Drug Administration
[online]
, (2008).
4. Levey, A. S. et al. Chronic kidney disease as a global public health problem: approaches and initiatives: a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 72, 247–259 (2007).
5. US National Library of Medicine. Clinicaltrials.gov
[online]
, (2014).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献